Raxatrigine free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 510347

CAS#: 934240-30-9 (free base)

Description: Raxatrigine, also known as vixotrigine, GSK1014802, and CNV1014802, is a small molecule state-dependent sodium channel blocker; Nav1.7 sodium channel inhibitor.


Chemical Structure

img
Raxatrigine free base
CAS# 934240-30-9 (free base)

Theoretical Analysis

MedKoo Cat#: 510347
Name: Raxatrigine free base
CAS#: 934240-30-9 (free base)
Chemical Formula: C18H19FN2O2
Exact Mass: 314.14
Molecular Weight: 314.360
Elemental Analysis: C, 68.77; H, 6.09; F, 6.04; N, 8.91; O, 10.18

Price and Availability

Size Price Availability Quantity
10mg USD -2
25mg USD -2
50mg USD 950
100mg USD 1450
200mg USD 2150
500mg USD 2950
1g USD 3750
2g USD 5650
5g USD 9950
Bulk inquiry

Related CAS #: 934240-31-0 (HCl)   934240-30-9 (free base)   934240-35-4 (mesylate)    

Synonym: GSK1014802; GSK 1014802; GSK-1014802; CNV1014802; CNV-1014802; CNV 1014802; Raxatrigine; Raxatrigine free base; Vixotrigine;

IUPAC/Chemical Name: (2S,5R)-5-(4-((2-fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide

InChi Key: JESCETIFNOFKEU-SJORKVTESA-N

InChi Code: InChI=1S/C18H19FN2O2/c19-15-4-2-1-3-13(15)11-23-14-7-5-12(6-8-14)16-9-10-17(21-16)18(20)22/h1-8,16-17,21H,9-11H2,(H2,20,22)/t16-,17+/m1/s1

SMILES Code: O=C(N)[C@H]1N[C@@H](C2=CC=C(OCC3=CC=CC=C3F)C=C2)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:   Related CAS# CAS#934240-31-0 ( Raxatrigine hydrochloride) CAS#934240-30-9 ( Raxatrigine free).      

Product Data:
Biological target: Raxatrigine is a sodium channel blocker and a Nav1.7 sodium channel inhibitor.
In vitro activity: This study demonstrates that raxatrigine enhances the inactivation but does not reduce the activation of Nav1.7 channels. Reference: Acta Pharmacol Sin. 2018 Apr;39(4):587-596. https://pubmed.ncbi.nlm.nih.gov/29094728/
In vivo activity: Orally administered raxatrigine for neuropathic pain is well-tolerated when administered as single doses up to 825 mg and multiple doses up to 450 mg twice daily. Reference: Clin Transl Sci. 2021 Jul;14(4):1272-1279. https://pubmed.ncbi.nlm.nih.gov/33278330/

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 83.0 264.04

Preparing Stock Solutions

The following data is based on the product molecular weight 314.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Zheng YM, Wang WF, Li YF, Yu Y, Gao ZB. Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. Acta Pharmacol Sin. 2018 Apr;39(4):587-596. doi: 10.1038/aps.2017.151. Epub 2017 Nov 2. PMID: 29094728; PMCID: PMC5888685. 2. Naik H, Steiner DJ, Versavel M, Palmer J, Fong R. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers. Clin Transl Sci. 2021 Jul;14(4):1272-1279. doi: 10.1111/cts.12935. Epub 2020 Dec 13. PMID: 33278330; PMCID: PMC8301589. 3. Witty DR, Alvaro G, Derjean D, Giblin GMP, Gunn K, Large C, Macpherson DT, Morisset V, Owen D, Palmer J, Rugiero F, Tate S, Hinckley CA, Naik H. Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia. ACS Med Chem Lett. 2020 Jul 16;11(9):1678-1687. doi: 10.1021/acsmedchemlett.0c00263. PMID: 32945812; PMCID: PMC7488392.
In vitro protocol: 1. Zheng YM, Wang WF, Li YF, Yu Y, Gao ZB. Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. Acta Pharmacol Sin. 2018 Apr;39(4):587-596. doi: 10.1038/aps.2017.151. Epub 2017 Nov 2. PMID: 29094728; PMCID: PMC5888685.
In vivo protocol: 1. Naik H, Steiner DJ, Versavel M, Palmer J, Fong R. Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of Vixotrigine in Healthy Volunteers. Clin Transl Sci. 2021 Jul;14(4):1272-1279. doi: 10.1111/cts.12935. Epub 2020 Dec 13. PMID: 33278330; PMCID: PMC8301589. 2. Witty DR, Alvaro G, Derjean D, Giblin GMP, Gunn K, Large C, Macpherson DT, Morisset V, Owen D, Palmer J, Rugiero F, Tate S, Hinckley CA, Naik H. Discovery of Vixotrigine: A Novel Use-Dependent Sodium Channel Blocker for the Treatment of Trigeminal Neuralgia. ACS Med Chem Lett. 2020 Jul 16;11(9):1678-1687. doi: 10.1021/acsmedchemlett.0c00263. PMID: 32945812; PMCID: PMC7488392.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, Zimmermann K,
Hoffmann T, Weidner C, Nassar MA, Alewood PF, Lewis RJ, Vetter I. Analgesic
Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated
Pain. Toxins (Basel). 2016 Mar 17;8(3). pii: E78. doi: 10.3390/toxins8030078.
PubMed PMID: 26999206; PubMed Central PMCID: PMC4810223.


2: Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA. Recent progress
in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug
15;24(16):3690-9. doi: 10.1016/j.bmcl.2014.06.038. Epub 2014 Jun 21. Review.
PubMed PMID: 25060923.


3: Zakrzewska JM, Palmer J, Ettlin DA, Obermann M, Giblin GM, Morisset V, Tate S,
Gunn K. Novel design for a phase IIa placebo-controlled, double-blind randomized
withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients
with trigeminal neuralgia. Trials. 2013 Nov 23;14:402. doi:
10.1186/1745-6215-14-402. PubMed PMID: 24267010; PubMed Central PMCID:
PMC4222641.